WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Ranbaxy announces launch of Atorvastatin, generic Lipitor®, in the U.S.

Details
Product
01 December 2011
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy"), today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market.
Read more ...

Forest Laboratories and Nycomed Receive Complete Response Letter for Roflumilast

Details
Product
19 May 2010
Forest Laboratories, Inc.Forest Laboratories, Inc. (NYSE: FRX) and Nycomed announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast.
Read more ...

Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)

Details
Product
23 March 2010
The Saudi food and Drug Authority has reviewed the safety of Rosiglitazone (Avandia®) which used in treatment of type 2 diabetes mellitus and marketed in Saudi Arabia as Avandia®.
Read more ...

Novel Drug for Chronic Management of Hyperuricemia in Gout Patients

Details
Product
10 March 2010
Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r).
Read more ...

FDA Grants IBsolvMIR Orphan Drug designation in the treatment of diabetes patients in the U.S.

Details
Product
25 November 2009
TikoMed AB, a biotechnology company focused on development and commercialization of innovative treatments for immune diseases and cell therapies, today announced that IBsolvMIR® has been granted orphan drug designation for the prevention of graft rejection of pancreatic islet transplantation by the U.S. Food and Drug Administration (FDA).
Read more ...

Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)

Details
Product
18 August 2009
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).
Read more ...

Schering-Plough Announces European Filing of SYCREST(R) (asenapine)

Details
Product
04 June 2009
Schering-Plough CorporationSchering-Plough Corporation (NYSE: SGP) announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder.
Read more ...

More Pharma News ...

  1. HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
  2. New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
  3. U.S. FDA Issues Complete Response Letter for SAPHRIS(TM)
  4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
  5. Trasylol® - One Thousand Lives A Month
  6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation
  7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R)
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Product

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.